FPR2 and breast carcinoma: However, conversely, Khau et al. found that FPR2 agonists, such as LXA4, promoted proliferation of MCF-7 and MDA-MB-231 breast cancer cells via the pro-survival and pro-proliferation PI3K/Akt signaling pathway [234].